BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFb Signaling to Durably Suppress Tumor GrowthCANCER RESEARCHIF16.62023-04-1910OAAI
BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibitionCANCER RESEARCHIF16.62023-04-040PRE
An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignanciesCANCER RESEARCHIF16.62023-04-040PRE